The Worldwide Lung Cancer Diagnostics Industry is Expected to Reach $3.6 Billion by 2027
DUBLIN, Dec. 29, 2021 /PRNewswire/ -- The "Lung Cancer Diagnostics Market Size, Share, Global Forecast 2022-2027, Industry Trends, Impact of COVID-19, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
Globally, lung cancer occurs when cells divide in the lungs uncontrollably - further causing tumours to grow, which reduces a person's ability to breathe and spread to other parts of the body.
Moreover, lung cancer is amongst the most common cancer and the leading cause of cancer-related death worldwide. Smoking is a significant risk factor, though everyone who develops lung cancer does not have a smoking history. Lung cancer can be fatal. Nevertheless, effective diagnoses and treatments are improving the outlook. According to the this research, Lung Cancer Diagnostics Market is projected to reach US$ 3.6 Billion by 2027.
Types of Lung Cancer Prevailing in the Global Market
The two chief types of lung cancer are small-cell lung cancer and non-small cell lung cancer, depending on their appearance under a microscope. Small cell lung cancer (SCLC) spreads promptly in the body, making detecting this cancer at an early stage. However, only about 10% of the fatalities are small cell lung cancers. There are two dominant subtypes of SCLC, combined small-cell lung carcinoma and small-cell lung carcinoma.
Non-small cell lung cancer (NSCLC) is the unique form of cancer and accounts for 85% of lung cancer cases. Moreover, multiple subtypes of NSCLC include large cell carcinoma, adenocarcinoma, squamous cell carcinoma, and other less frequent types of NSCLCs. As per our analysis, non-small cell lung cancer dominates small cell lung cancer around the world.
Worldwide Lung Cancer Diagnosis Industry will grow with a CAGR of 7.75% during 2021 to 2027
Imaging tests activity is the primary screening technique used for lung cancer diagnosis. Imaging tests assist as the initial screening mechanism for lung cancer diagnostics and are helpful throughout the treatment period. Wherein the high usage rates of various imaging techniques, including X-rays, Magnetic resonance imaging (MRI) scans (which use magnetic fields), Ultrasound (which uses sound waves) and Nuclear tests (which use radioactive substances to trace) are involved. Moreover, if cancer has spread, imaging tests can also reveal changes to bones and other organs. Consequently, helping to track treatment progress and capture the highest market share in the Lung Cancer Diagnostics Market.
Global Lung Cancer Diagnostics Market Size was US$ 2.3 Billion in 2021
Globally, lung cancer patients visit the hospitals & clinics for cancer-related and unrelated reasons more often than patients visiting diagnostics centres and research institutes with their lung cancer-related issues. Further, this results in the dominance of the hospitals & clinics dealing in admissions and lung cancer diagnosis. Moreover, as the patients frequently require emergency medical care due to acute unbearable symptoms and life-threatening conditions, hospitals & clinics serve as immediate help. As per our analysis, hospitals dominate the end-user segment in the Lung Cancer Diagnostics Market.
North America is the largest Lung Cancer Diagnosis Market and expected to remain its dominance in forecast period
North America, Europe and the Asia Pacific are analyzed at the regional forefront in the report. As per our analysis, North America is identified as the largest regional market with the highest market share throughout the forecasted period. The largest market share is attributed to the increased market invasion rates of technologically advanced products, the increasing patient awareness, and the growing smoking prevalence level in the region.
Competitive Landscape Existing in the Market
The lung cancer diagnostics market is highly fragmented, with a large number of local and international players. Key players adopt different growth policies to magnify their market presence, including partnerships, agreements, collaborations, new product launches, geographical augmentations, mergers and acquisitions. Some of the chief players in the industry are Illumina, Inc., Abbott Laboratories, Thermo Fisher Scientific, Inc, QIAGEN N.V. and Roche Holding AG.
COVID-19 Pandemic affect on the Lung Cancer Diagnostics
At the origin of the COVID-19 pandemic, elective medical procedures, including lung cancer screening, were principally put on hold to prioritize urgent necessities and reduce the risk of the spread of COVID-19 in healthcare settings at the beginning of 2021. One effect of this has been a significant drop in the lung cancer diagnostics industry compared to 2020 as the pandemic started spreading at a rapid pace in H1 of 2021. Most healthcare facilities were offering elective procedures again, including lung cancer diagnostic declining the all over market in 2021.
Company Analysis:
1. llumina, Inc.
2. Abbott Laboratories
3. Thermo Fisher Scientific, Inc
4. QIAGEN N.V.
5. Roche Holding AG.
Key Topics Covered:
1. Introduction
2. Research & Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global Lung Cancer Diagnostics Market
6. Market Share Analysis
6.1 Diagnosis Test Type
6.2 Lung cancer Type
6.2.1 Non-Small-cell Lung Cancer Diagnostics Types
6.3 End-User
6.4 Regions
7. Diagnosis Test Type - Global Lung Cancer Diagnostics Market
7.1 Imaging Test
7.2 Biopsy
7.3 Sputum Cytology
7.4 Molecular Test
7.5 Others
8. Lung Cancer Type - Global Lung Cancer Diagnostics Market
8.1 Small-cell Lung Cancer Diagnostics
8.2 Non-Small-cell Lung Cancer Diagnostics
8.2.1 Adenocarcinoma
8.2.2 Squamous Cell Carcinoma
8.2.3 Large cell carcinoma
8.2.4 Others and not otherwise specified
9. End-User - Global Lung Cancer Diagnostics Market
9.1 Hospitals & Clinics
9.2 Diagnostic Centers
9.3 Research Institute
9.4 Others
10. Regions - Global Lung Cancer Diagnostics Market
10.1 North America
10.2 Europe
10.3 Asia Pacific
10.4 ROW
11. Company Analysis
11.1 llumina, Inc..
11.1.1 Overviews
11.1.2 Recent Developments
11.1.3 Revenues
11.2 Abbott Laboratories
11.2.1 Overviews
11.2.2 Recent Developments
11.2.3 Revenues
11.3 Thermo Fisher Scientific, Inc
11.3.1 Overviews
11.3.2 Recent Developments
11.3.3 Revenues
11.4 QIAGEN N.V.
11.4.1 Overviews
11.4.2 Recent Developments
11.4.3 Revenues
11.5 Roche Holding AG.
11.5.1 Overviews
11.5.2 Recent Developments
11.5.3 Revenues
For more information about this report visit https://www.researchandmarkets.com/r/8gc8h1
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article